With sales of its COVID-19 vaccines on the wane, Moderna has showcased the projects it will look to for the next phase of its development, headed by new vaccines for influenza and respiratory syncytial virus (RSV).In its annual R&D update, the biotech said that late-stage quadrivalent flu shot mRNA-1010 stimulated immune responses against all four […]
